PFE acquires MDVN for $81.50/sh in cash—a 118% premium relative to the closing price on 3/30/16 (when the price started rising in anticipation of a buyout):
The nominal deal value is $14.0B. There is no CVR for Talazoparib, but MDVN’s webcast on 7/6/16 may have helped boost the buyout price (#msg-123722679).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.